GlassScriptPhysician profile
Raymond K Pate
NPI 1659692234
$5,282.87
in general payments reported to CMS, 2019-2025
33 companies · $917 in 2025
The $917 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.11 · 2021: $12.29 · 2022: $879 · 2023: $1,822 · 2024: $1,601 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,224 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,224.22 |
| Education | $115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,146.85 | 2022-2025 | |
| Novo Nordisk INC | $769.11 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $424.55 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $418.53 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $325.32 | 2022-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $318.51 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.03 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $190.05 | 2019-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $176.25 | 2023-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $149.45 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $112.73 | 2022-2024 | |
| Axsome Therapeutics, INC. | $109.94 | 2023-2025 | Auvelity, Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $97.69 | 2022 | |
| Exact Sciences Corporation | $96.80 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $84.01 | 2022-2024 | Ajovy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $82.69 | 2022-2024 | Injectafer |
| Antares Pharma, INC. | $71.92 | 2024-2025 | Xyosted |
| Gilead Sciences, INC. | $60.28 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.36 | 2023-2024 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $57.25 | 2022 | |
| Scpharmaceuticals INC. | $44.24 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.60 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $31.52 | 2024 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $25.44 | 2022 | |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
| Genentech USA, INC. | $23.83 | 2019-2021 | |
| Abbott Laboratories | $21.35 | 2024 | Freestyle Libre 3 |
| Dynavax Technologies Corporation | $19.74 | 2025 | Heplisav-B |
| Xeris Pharmaceuticals, INC. | $17.04 | 2024 | Gvoke Hypopen |
| Corcept Therapeutics | $17.03 | 2025 | Korlym |
| Ironshore Pharmaceuticals INC. | $14.44 | 2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $13.24 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Pate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.